Abstract 72P
Background
Ado-trastuzumab emtansine (T-DM1) became the first FDA approved antibody-drug conjugate in breast cancer. This real-world study aimed to evaluate the efficacy and safety of first approved T-DM1 biosimilar (ZRC-3256) in India for HER2-positive breast cancer in routine practice.
Methods
It was a retrospective, single-center, observational study and included patients treated between May 2021 to December 2022. Eligible patients were all female with HER2-positive metastatic breast cancer treated with trastuzumab and taxane prior and at progression treated with standard dose T-DM1 biosimilar. Brain metastasis patients treated with appropriate local therapy were allowed. The primary endpoint includes response rate and progression-free survival (PFS). The secondary endpoints were time to treatment failure (TTF), safety and overall survival (OS). Descriptive statistics were used to recapitulate the patient and other related characteristics. The study was approved by the institute ethics committee.
Results
30 patients treated with T-DM1 biosimilar were included. 5 among them had brain involvement. Median age was 57 years, all had received prior HER2-targeted therapy (100%) and majority of patients (86.67%) were post-menopausal. 83.3% patients received T-DM1 therapy in 2nd line and the complete response rate was 66.63%. Median progression free survival and time to treatment failure were found to be around 13.5 months (95% CI: 13.46 – 17.17) and 13 months (95% CI: 11.47 – 14.53) respectively. Median overall survival data is yet to mature and stand at 24 months (95% CI: 21.03 – 26.97) with limited events. Common adverse events were elevated transaminases, anemia, and thrombocytopenia, with most being manageable and reversible. 10% patients experienced adverse events of Grade 3 or above.
Conclusions
The study findings suggested that T-DM1 is effective in managing HER2-positive metastatic breast cancer and the outcomes with T-DM1 biosimilar usage in the real world are consistent with the published evidence of randomized controlled clinical trials with T-DM1. So, this biosimilar can be a reasonable option in routine clinical practice in India.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract